News
Singapore’s Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab) for the prevention ...
Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback